Late-stage Parkinson's disease for the rehabilitation specialist: A nursing perspective

Topics in Geriatric Rehabilitation

Volumn 21, Issue 3, 2005, Pages 233-246

  Calne, Susan M ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Late stage Parkinson's disease; Rehabilitation

Indexed keywords

AMANTADINE; ANTIHYPERTENSIVE AGENT; ANTIPARKINSON AGENT; APO TRIHEX; BENSERAZIDE PLUS LEVODOPA; BENZATROPINE MESILATE; BOTULINUM TOXIN; BROMOCRIPTINE MESILATE; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; HALOPERIDOL; LAXATIVE; LEVODOPA; METOCLOPRAMIDE; OLANZAPINE; PERGOLIDE MESILATE; PRAMIPEXOLE; PROCHLORPERAZINE MALEATE; RISPERIDONE; ROPINIROLE; SELEGILINE; TRIHEXYPHENIDYL;

AGE; AGED; ANOREXIA; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; CONFUSION; CONSTIPATION; DAILY LIFE ACTIVITY; DELUSION; DIARRHEA; DIPLOPIA; DISEASE ACTIVITY; DISEASE COURSE; DIZZINESS; DOSE RESPONSE; DRUG RESPONSE; DYSARTHRIA; DYSKINESIA; HALLUCINATION; HUMAN; HYPERSALIVATION; HYPOTENSION; INHERITANCE; INSOMNIA; LIVEDO RETICULARIS; MOTOR DYSFUNCTION; MUSCLE CRAMP; MUSCLE RIGIDITY; NAUSEA; NIGHTMARE; NURSING; ON OFF EFFECT; ORTHOSTATIC HYPOTENSION; PALLIDOTOMY; PARKINSON DISEASE; PSYCHOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; SYMPTOM; SYNCOPE; THALAMOTOMY; URINE RETENTION; VISUAL IMPAIRMENT; VIVID DREAM; VOLUNTARY MOVEMENT; VOMITING; WEARING OFF EFFECT; WITHDRAWAL SYNDROME; XEROSTOMIA;

EID: 23844515412     PISSN: 08827524     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013614-200507000-00010     Document Type: Review

References (73)

1. Rajput AH, Pahwa R, Pahwa P, Rajput A. Prognostic significance of the onset mode in parkinsonism. Neurology. 1993;43(4):829-830.
2. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry. 2001;16(5):528-536.
3. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427-442.
4. Calne DB. Parkinson's disease is not one disease. Parkinsonism Relat Disord. 2000;7(1):3-7.
5. Hattori N, Kitada T, Matsumine H, et al. Molecular genetic analysis of a novel Parkin gene in Japanese families with autosomal recessive juvenile parkinsonism: evidence for variable homozygous deletions in the Parkin gene in affected individuals. Ann Neurol. 1998;44(6):935-941.
6. Mizuno Y, Hattori N, Mori H. Genetics of Parkinson's disease [Review]. Biomed Pharmacother. 1999; 53(3):109-116.
7. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science. November 15, 1996;274:1197-1198.
8. Zimprich A, Muller-Myhsok B, Farrer M, et al. The PARKS locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval. Am J Hum Genet. 2004;74(1):11-19.
9. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study [see comments]. JAMA. 1999;281(4):341-346.
10. Kumar A, Calne SM, Schulzer M, et al. Clustering of Parkinson disease: shared cause or coincidence? Arch Neurol. 2004;61(7):1057-1060.
11. Tsui JKC, Calne DB, Wang Y, Schulzer M, Marion SA. Occupational risk factors in Parkinson's disease. Can J Public Health. 1999;90(5):334-335.
12. Tanner CM. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol. 2003;91:133-142.
13. Lee CS, Schulzer M, Mak EK, et al. Clinical observations on the rate of progression of idiopathic parkinsonism. Brain. 1994;117:501-507.
14. Schulzer M, Lee CS, Mak EK, Vingerhoets FJG, Calne DB. A mathematical model of pathogenesis in idiopathic parkinsonism. Brain. 1994;117:509-516.
15. Wagner ML, Fedak MN, Sage JI, Mark MH. Complications of disease and therapy: a comparison of younger and older patients with Parkinson's disease. Ann Clin Lab Sci. 1996;26(5):389-395.
16. Schrag A, Ben-Schlomo Y, Brown R, Marsden CD, Quinn N. Young-onset Parkinson'sdisease revisited-Clinical features, natural history and mortality. Mov Disord. 1998;13(6):885-894.
17. Schenkman M, Donovan J, Tsubota J, Kluss M, Stebbins P, Butler RB. Management of individuals with Parkinson's disease: rationale and case studies. Phys Ther. 1989;69(11):944-955.
18. Calne SM, Baisley K, Coughlan P, Shaw C, Traviss K. Taking Charge: A Guide to Living With Parkinson's. Vancouver; Parkinson Society British Columbia; 2005.
19. Calne SM, Mak E, Hall J, et al. Validating a Quality of Life Rating Scale in caregivers of patients with Parkinson's disease: Parkinson's Impact Scale (PIMS). Adv Neurol 2002;91:115-121.
20. Maier K, Calne SM. Informal caregiving: a valuable part of the health care team. In: Ebadi M, Pfeiffer RF, eds. Parkinson's Disease. Boca Raton, Fla: CRC Press; 2005:999-1008.
21. Calne SM. The psychosocial impact of late-stage Parkinson's disease. J Neurosci Nurs. 2003;35(6): 306-313.
22. Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004;363(9423):1783-1793.
23. Ashkan K, Wallace B, Bell BA, Benabid AL. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease 1993-2003: where are we 10 years on? Br J Neurosurg. 2004;18(1):19-34.
24. Calne SM, Kumar A. Nursing care of patients with late-stage Parkinson's disease. J Neurosci Nurs. 2003;35(5):242-251.
25. Calne S. Nursing care of patients with idiopathic parkinsonism. Nurs Times. 1994;90(24):38-39.
26. Calne S. Examining causes and care of idiopathic parkinsonism. Nurs Times. 1994;90(16):38-40.
27. Fuente-Fernandez R, Schulzer M, Mak E, Calne DB, Stoessl AJ. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model. Brain. 2004;127(Pt 4):888-899.
28. Pal PK, Calne DB, Calne S, Tsui JKC. Botulinum toxin A as treatment for drooling saliva in PD. Neurology. 2000;54:244-247.
29. Friedman A, Potulska A. Quantative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat Disord. 2001;7(4):329-332.
30. Logemann JA, Pauloski BR, Colangelo L, Lazarus C, Fujiu M, Kahrilas PJ. Effects of a sour bolus on oropharyngeal swallowing measures in patients with neurogenic dysphagia. J Speech Hear Res. 1995;38(3):556-563.
31. Cushing ML, Traviss KA, Calne SM. Parkinson's disease: implications for nutritional care. Can J Dietetic Pract Res. 2002;63(2):81-87.
32. Keizer AA. Percutaneous endoscopic gastrostomy catheter: a trap. Nederlands Tijdschrift voor Geneeskunde. 2001;145(42):2009-2010.
33. Sharkawi AE, Ramig L, Logemann JA, et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry. 2002;72(1):31-36.
34. Cornelia CL, Nardine TM, Diederich NJ, Stebbins GT. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology. 1998;51(2):526-529.
35. Dowling GA. Sleep in older women with Parkinson's disease. J Neurosci Nurs. 1936;27(6):355-357.
36. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA. 2002;287(4):455-463.
37. Larsen JP, Tandberg E. Sleep disorders in patients with Parkinson's disease: epidemiology and management. CNS Drugs. 2001;15(4):267-275.
38. Pal PK, Calne SM, Flemming J, Brown T, Calne DB. Sleep disturbances in patients with Parkinson's disease and their caregivers. Parkinson's Dis Relat Disord. 2001;7(S1):353.
39. Pal PK, Calne S, Samii A, Fleming JAE. A review of normal sleep and its disturbances in Parkinson's disease. Parkinsonism Relat Disorct. 1999;5:1-17.
40. Sanjiv CC, Schulzer M, Mak E, et al. Daytime somnolence in patients with Parkinson's disease. Parkinsonism Relat Disord. 2001;7(4):283-287.
41. Smith MC, Ellgring H, Oertel WH. Sleep disturbances in Parkinson's disease patients and spouses. J Am Geriatric Soc. 1997;45(2):194-199.
42. Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson's disease: a meta-analysis of randomised controlled trials. Drug Safety. 2001;24(11):863-868.
43. Happe S, Schrodl B, Faltl M, Muller C, Auff E, Zeitlhofer J. Sleep disorders and depression in patients with Parkinson's disease. Acta Neurol Scand. 2001;104(5):275-280.
44. Uitti RJ, Wszolek ZK. Dopamine agonists, sleep disorders, and driving in Parkinson's disease. Adv Neurol. 2003;91:343-349.
45. Teel CS, Press AN. Fatigue among elders in caregiving and noncaregiving roles. West J Nurs Res. 1999;21(4):498-514.
46. Hutton JT, Morris JL, Elias JW, Varma R, Poston JN. Spatial contrast sensitivity is reduced in Parkinson's disease. Neurology. 1991;41:1200-1202.
47. Chandiramani VA, Palace J, Fowler CJ. How to recognize patients with parkinsonism who should not have urological surgery. Br J Urol. 1997;80(1):100-104.
48. Pepper PV, Goldstein MK. Postoperative complications in Parkinson's disease. J Am Geriatr Soc. 1999;47(8):967-972.
49. Ashraf W, Wszolek ZK, Pfeiffer RF, Normand M, Maurer K, Srb F. Anorectal function in fluctuating (on-off) Parkinson's disease: evaluation by combined anorectal manometry and electromyography. Mov Disord. 1995;10(5):650-657.
50. Marinella MA. Acute colonic pseudo-obstruction complicated by cecal perforation in a patient with Parkinson's disease. South Med J. 1997;90(10):1023-1026.
51. Pfeiffer RF, Quigley EMM. Gastrointestinal motility problems in patients with Parkinson's disease-Epidemiology, pathophysiology, and guidelines for management. CNS Drugs. 1999;11(6):435-448.
52. Rosenthal MJ, Marshall CE. Sigmotd volvulus in association with parkinsonism. Report of four cases. J Am Geriatr Soc. 1987;35(7):683-684.
53. Dargent-Molina P, Favier F, Grandjean H, et al. Fall-related factors and risk of hip fracture: the EPIDOS prospective study. Lancet. 1996;348(9021):145- 149.
54. Kannus P, Parkkari J, Niemi S, et al. Prevention of hip fracture in elderly people with use of a hip protector. New Engl J Med. 2000;343(21):1506- 1513.
55. Rubenstein L. Hip protectors - A breakthrough in fracture prevention. N Engl J Med. 2000;343(21): 1562-1563.
56. Visentin R Ciravegna R, Corcelli F, Fabris F. Cost-effectiveness of hip fracture prevention. Epidemiol Prev. 1998;22(1):44-48.
57. Lorrain J, Paiement G, Chevrier N, et al. Population demographics and socioeconomic impact of osteoporotic fractures in Canada. Menopause. 2003;10(3):228-234.
58. Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Physician. 2003;67(7):1521-1526.
59. Easdown LJ, Tessler MJ, Mimik J. Upper airway involvement in Parkinson's disease resulting in post-operative respiratory failure. Can J Anaesth. 1995; 42(4):344-347.
60. Galvez-Jimenez N, Lang AE. The perioperative management of Parkinson's disease revisited. Neurol Clin. 2004;22(2):367-377.
61. Rogers MW. Disorders of posture, balance, and gait in Parkinson's disease. Clin Geriatr Med. 1996;12(4): 825-845.
62. Onrot J. Therapeutic Choices. 2nd ed. Toronto, Ontario: Canadian Association of Pharmacists; 1998.
63. Calne S, Hurwitz TA. Adjustment, Adaptation, and Accommodation: Psychosocial Approaches to Living With Parkinson's Disease. Miami; National Parkinson Foundation; 1997.
64. Andersen S. Patient perspective and self-help. Neurology. 1999;52(7, suppl 3):S26-S28.
65. Montgomery E. Rehabilitative approach to Parkinson's disease. Parkinsonism Relat Disord. 2004;10: S43-S47.
66. Calne S. Nursing care of patients with idiopathic parkinsonism. Nurs Times. 1994;90:38-39.
67. Calne DB. Treatment of Parkinson's disease. N Engl J Med. 1993;329:1021-1027.
68. Calne DB, Calne S. Treatment of Parkinson's disease. In: Ancil RJ, Holliday SG, Mithani AH, eds. Therapeutics in Geriatric Neuropsychiatry. Chichester, England: John Wiley & Sons Ltd; 1997:1-12.
69. Hurwitz TA, Calne SM. Depression, anxiety and psychosis in Parkinson's disease. Br Columbia Med J. 2001;43(4):214-218.
70. Cummings JL. The dementias of Parkinson's disease: prevalence, characteristics, neurobiology, and comparison with dementia of the Alzheimer type. Eur Neurol. 1988;28(suppl 1):15-23.
71. Cummings JL. Managing psychosis in patients with Parkinson's disease [letter; comment]. N Engl J Med. 1999;340(10):801-803. See comments.
72. Nordstrom M, Lubkin I. Quality of life. In: Lubkin IM, ed. Chronic Illness: Impact and Interventions. Boston: Jones & Bartlett; 1990:136-153.
73. Gorell JM, Johnson CC, Rybicki BA. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology. 1994;44(10):1865-1868.